These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34758246)

  • 21. Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program.
    Socal MP; Wang Y; Plummer E; Anderson GF; Bai G
    JAMA; 2024 Jan; 331(1):72-75. PubMed ID: 38095888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
    Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
    Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
    Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
    Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost minimization of medicare part D prescription drug plan expenditures.
    Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
    Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Top 40 Medicare Part D prescription drugs Ranked by total payments in 2014.
    Mod Healthc; 2016 Oct; 46(36):42. PubMed ID: 30398720
    [No Abstract]   [Full Text] [Related]  

  • 26. Can increases in CHIP copayments reduce program expenditures on prescription drugs?
    Sen B; Blackburn J; Morrisey M; Becker D; Kilgore M; Caldwell C; Menachemi N
    Medicare Medicaid Res Rev; 2014; 4(2):. PubMed ID: 24967148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
    Lakdawalla D; Li M
    JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceuticals and Medical Devices: Medicare Part D.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252885
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
    Cheng LI; Rascati KL
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managed care outlook. Rising deductibles for Part D beneficiaries.
    Manag Care; 2008 Dec; 17(12):49. PubMed ID: 19127768
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
    Dusetzina SB; Conti RM; Yu NL; Bach PB
    JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116794
    [No Abstract]   [Full Text] [Related]  

  • 35. A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D.
    Gellad WF; Ennis M; Kuza CC
    N Engl J Med; 2019 May; 380(18):1688-1690. PubMed ID: 30946552
    [No Abstract]   [Full Text] [Related]  

  • 36. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017.
    Hwang TJ; Dusetzina SB; Feng J; Maini L; Kesselheim AS
    JAMA; 2019 Jul; 322(3):267-269. PubMed ID: 31310287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of the coverage gap on drug spending: a closer look at Medicare Part D.
    Zhang Y; Donohue JM; Newhouse JP; Lave JR
    Health Aff (Millwood); 2009; 28(2):w317-25. PubMed ID: 19189991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-31. PubMed ID: 29361657
    [No Abstract]   [Full Text] [Related]  

  • 40. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.